Multidose pharmacokinetics of factor IX: implications for dosing in prophylaxis.
about
The History of Clotting Factor Concentrates PharmacokineticsPharmacokinetics of plasma-derived and recombinant factor IX: using population pharmacokinetics with sparse sampling data needs further study.Clinical utility and patient perspectives on the use of extended half-life rFIXFc in the management of hemophilia B.Prophylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspective.The pharmacokinetics of clotting factor therapy.Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients.Use of pharmacokinetics in the coagulation factor treatment of patients with haemophilia.New treatments in hemophilia: insights for the clinician.Population pharmacokinetic modelling of recombinant factor IX Fc fusion protein (rFIXFc) in patients with haemophilia B.Personalized prophylaxis.Population pharmacokinetic modelling of factor IX activity after administration of recombinant factor IX in patients with haemophilia B.Population pharmacokinetics of plasma-derived factor IX: procedures for dose individualization.Clinical efficacy, safety and pharmacokinetic properties of the plasma-derived factor IX concentrate Haemonine in previously treated patients with severe haemophilia B.Alprolix (recombinant Factor IX Fc fusion protein): extended half-life product for the prophylaxis and treatment of hemophilia B.Experience with a new percutaneous port system, Percuseal, for intravenous injection in patients with haemophilia, von Willebrand disease and severe alpha1-antitrypsin deficiency.Prophylaxis in factor IX deficiency product and patient variation.Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized.In vivo recovery of factor VIII and factor IX: intra- and interindividual variance in a clinical setting.A commentary on the differences in pharmacokinetics between recombinant and plasma-derived factor IX and their implications for dosing.A clinical study assessing the pharmacokinetics, efficacy and safety of AlphaNine(®) , a high-purity factor IX concentrate, in patients with severe haemophilia B.Individualized factor IX dosing in two brothers: application of longitudinal pharmacokinetic modelling to optimize therapeutic benefit.Simoctocog alfa for the treatment of hemophilia A.Pharmacokinetics of recombinant factor IX in relation to age of the patient: implications for dosing in prophylaxis.Population pharmacokinetics of plasma-derived factor IX in adult patients with haemophilia B: implications for dosing in prophylaxis.A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia.History of prophylaxis.Population pharmacokinetics of recombinant factor VIII Fc fusion protein.Tailored pharmacokinetic dosing allows self-administration and reduces the cost of IV augmentation therapy with human alpha(1)-antitrypsin.Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerations
P2860
Q30235127-0B3114D6-A4EA-41D9-928E-6753B8FF69C2Q30685072-6EF64132-E0FB-4043-88A5-14228110E25EQ34045763-A0C8FD9D-8A23-4CFF-9A51-66DFAC36B9B2Q35112459-3DB8C74C-3712-4332-8A9F-625F9345E073Q35163599-B547466E-4FF8-43EF-A9E9-873AED9F6B6CQ35692016-8DE7F0AA-2476-42FE-89CB-42DE5B2E745EQ36291059-D9F5E3C0-DAE3-4AE7-A977-5387B79E15BDQ36612681-8A237F35-8114-49C7-B905-78C06BD22456Q38935228-A0D6126A-EDAD-42B3-8A57-DDE0CFF7176FQ39596251-0F1EB17B-E62B-4E80-9275-DA0AF4BFA71BQ39647561-5B2E5276-3B91-4960-81F5-3ED71A2C1429Q40066317-460B6322-9FFB-40A7-B645-2B440A13F185Q42611760-A9EAD7CD-3132-448C-9F37-8DC3798836DBQ44051815-38682336-4EAC-4F9F-A63D-DA664A0080CAQ44676673-074F645F-A4D6-4794-A6AB-D96FF491FE4BQ45861566-E3C86E12-6893-4718-ACC0-66502FB57A35Q45863345-113EC485-0DB2-42A3-9683-7150C129BDA6Q45864852-1054A4ED-303A-4195-BEC0-A4F21487D18DQ45866870-0F075E05-4828-4AC6-B176-B29B198D2F0EQ45866906-A47EA6A7-0DA3-4C1E-8A00-68F321057516Q45870386-67F9D477-366F-4C55-8C09-B6780CFFC3FBQ45873366-3D56F826-1E46-44CB-9B7F-30BBD6918B1AQ45875808-5E8221FB-3FA0-4178-86AE-AAF4616E2B3AQ45876681-60A3B276-DB91-4A85-9FF6-922C88E6B9B7Q45879737-E2A01EC7-EDC8-4CD9-A252-455FF8E35516Q45885182-D7539496-B093-47D7-8CA3-C4B3EF22A283Q45885620-A9FAFFA3-E1FA-4CA4-BA38-DC51613464FFQ50718662-E4A33D5B-22FE-4D14-AB4B-9BCEA9E49705Q57179210-263A9C30-E8E5-4183-9ADD-31CC1D57AFF0
P2860
Multidose pharmacokinetics of factor IX: implications for dosing in prophylaxis.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
Multidose pharmacokinetics of factor IX: implications for dosing in prophylaxis.
@en
Multidose pharmacokinetics of factor IX: implications for dosing in prophylaxis.
@nl
type
label
Multidose pharmacokinetics of factor IX: implications for dosing in prophylaxis.
@en
Multidose pharmacokinetics of factor IX: implications for dosing in prophylaxis.
@nl
prefLabel
Multidose pharmacokinetics of factor IX: implications for dosing in prophylaxis.
@en
Multidose pharmacokinetics of factor IX: implications for dosing in prophylaxis.
@nl
P2093
P2860
P1433
P1476
Multidose pharmacokinetics of factor IX: implications for dosing in prophylaxis.
@en
P2093
Berntorp E
Björkman S
Carlsson M
P2860
P356
10.1046/J.1365-2516.1998.00173.X
P577
1998-03-01T00:00:00Z